Intensive immunosuppression with cyclophosphamide in multiple sclerosis. Follow up of 110 patients for 2-6 years.
作者信息
Gonsette R E, Demonty L, Delmotte P
出版信息
J Neurol. 1977 Feb 17;214(3):173-81. doi: 10.1007/BF00316148.
PMID:65452
Abstract
140 MS patients were treated with intensive I.V. cyclophosphamide immunotherapy and 110 were followed over 2-4 years. Annual relapse rate incidence was calculated over a period of 2 years before and after treatment and repeated neurological scores were made during this period. The conclusions are that 62% of the patients were stabilized during 2-4 years and that clinical improvement of the neurological signs was observed in most of the cases. It is concluded that intensive immunosuppression is able to interfere with the pathological processes involved in the pathogenesis of disseminated sclerosis.
摘要
相似文献
1
Intensive immunosuppression with cyclophosphamide in multiple sclerosis. Follow up of 110 patients for 2-6 years.
J Neurol. 1977 Feb 17;214(3):173-81. doi: 10.1007/BF00316148.
2
Effect of intensive immunosuppression on the course of chronic progressive multiple sclerosis.强化免疫抑制对慢性进行性多发性硬化病程的影响。
J Neurol. 1980;223(3):177-90. doi: 10.1007/BF00313182.
3
Experience with cyclophosphamide in multiple sclerosis: the cons.环磷酰胺治疗多发性硬化症的经验：反面观点
Neurology. 1988 Jul;38(7 Suppl 2):14-8.
4
Cyclophosphamide in relapsing remitting multiple sclerosis.环磷酰胺用于复发缓解型多发性硬化症。
Ital J Neurol Sci. 1990 Jun;11(3):271-4. doi: 10.1007/BF02333857.
5
Short-term intensive cyclophosphamide treatment in progressive multiple sclerosis.
Ital J Neurol Sci. 1987 Dec;8(6):589-92. doi: 10.1007/BF02333666.
6
The effect of cyclophosphamide on T lymphocytes and T lymphocyte subsets in patients with chronic progressive multiple sclerosis.环磷酰胺对慢性进行性多发性硬化症患者T淋巴细胞及T淋巴细胞亚群的影响。
Acta Neurol Scand. 1984 Feb;69(2):90-6. doi: 10.1111/j.1600-0404.1984.tb07784.x.
7
8
Intense immunosuppression in chronic progressive multiple sclerosis: the Kaiser study.慢性进展性多发性硬化症中的强化免疫抑制：凯撒研究
J Neurol Neurosurg Psychiatry. 1991 Dec;54(12):1055-60. doi: 10.1136/jnnp.54.12.1055.
9
Short-term intensive cyclophosphamide treatment in multiple sclerosis. A retrospective controlled study.
J Neurol. 1981;225(2):119-33. doi: 10.1007/BF00313325.
10
Moving on to second-line therapies in pediatric MS: Immunosuppression with cyclophosphamide.
Neurology. 2009 Jun 16;72(24):2064-5. doi: 10.1212/WNL.0b013e3181a92caa. Epub 2009 May 13.
引用本文的文献
1
Multiple Sclerosis in Children: Differential Diagnosis, Prognosis, and Disease-Modifying Treatment.儿童多发性硬化症：鉴别诊断、预后及疾病修正治疗
CNS Drugs. 2022 Jan;36(1):45-59. doi: 10.1007/s40263-021-00887-w. Epub 2021 Dec 23.
2
Therapy of Pediatric-Onset Multiple Sclerosis: State of the Art, Challenges, and Opportunities.儿童期多发性硬化症的治疗：现状、挑战与机遇
Front Neurol. 2021 May 17;12:676095. doi: 10.3389/fneur.2021.676095. eCollection 2021.
3
From Leflunomide to Teriflunomide: Drug Development and Immunosuppressive Oral Drugs in the Treatment of Multiple Sclerosis.从来氟米特到特立氟胺：多发性硬化治疗中的药物研发及免疫抑制口服药物
Curr Neuropharmacol. 2017;15(6):874-891. doi: 10.2174/1570159X14666161208151525.
4
Role of immunosuppressive therapy for the treatment of multiple sclerosis.免疫抑制疗法在多发性硬化治疗中的作用。
Neurotherapeutics. 2013 Jan;10(1):77-88. doi: 10.1007/s13311-012-0172-3.
5
Treatment of relapsing-remitting multiple sclerosis with high-dose cyclophosphamide induction followed by glatiramer acetate maintenance.大剂量环磷酰胺诱导缓解后用醋酸格拉替雷维持治疗复发性缓解型多发性硬化症。
Mult Scler. 2012 Feb;18(2):202-9. doi: 10.1177/1352458511419701. Epub 2011 Aug 24.
6
Lights and shadows of cyclophosphamide in the treatment of multiple sclerosis.环磷酰胺治疗多发性硬化症的利弊
Autoimmune Dis. 2011 Mar 15;2011:961702. doi: 10.4061/2011/961702.
7
Immunomodulatory therapies in neurologic critical care.神经危重症中的免疫调节治疗。
Neurocrit Care. 2010 Feb;12(1):132-43. doi: 10.1007/s12028-009-9274-0. Epub 2009 Sep 23.
8
Cyclophosphamide therapy in pediatric multiple sclerosis.儿童多发性硬化症的环磷酰胺治疗
Neurology. 2009 Jun 16;72(24):2076-82. doi: 10.1212/WNL.0b013e3181a8164c. Epub 2009 May 13.
9
Cyclophosphamide for multiple sclerosis.环磷酰胺用于治疗多发性硬化症。
Cochrane Database Syst Rev. 2007 Jan 24;2007(1):CD002819. doi: 10.1002/14651858.CD002819.pub2.
10
The combination of cyclophosphamide plus interferon beta as rescue therapy could be used to treat relapsing-remitting multiple sclerosis patients-- twenty-four months follow-up.环磷酰胺联合β-干扰素作为挽救疗法可用于治疗复发缓解型多发性硬化症患者——24个月随访。
J Neurol. 2005 Oct;252(10):1255-61. doi: 10.1007/s00415-005-0857-1. Epub 2005 Jun 6.
本文引用的文献
1
[Immunodepressive therapy in neurology].
Presse Med (1893). 1967 Apr 22;75(19):967-8.
2
[Multiple sclerosis and the autoimmunization process. Treatment by antimitotics].
Lyon Med. 1966 Feb 6;215(6):345-52.
3
A preliminary evaluation of azathioprine (Imuran) in the treatment of multiple sclerosis.
Henry Ford Hosp Med J. 1969 Summer;17(2):89-92.
4
[Immunosuppressive agents in multiple sclerosis. Preliminary trials with Proresid].
Wien Med Wochenschr. 1968 Nov 2;118(44):934-7.
5
[Experiences with cytostatic agents in multiple sclerosis].
Wien Klin Wochenschr. 1970 Oct 5;82(40):697-9.
6
[Treatment of multiple sclerosis with intraspinal antilymphocyte serum: theoretical bases; opportunities for utilization].
Rev Neurol (Paris). 1970 Jul;123(1):65-72.
7
Transformation of lymphocytes from patients with multiple sclerosis. Use of encephalitogen of human origin, with a report of a trial of immunosuppressive therapy in multiple sclerosis.
Arch Neurol. 1970 Jul;23(1):32-40. doi: 10.1001/archneur.1970.00480250036006.
8
[Immunosuppressive therapy of multiple sclerosis. 1. Preliminary communication on the results of treatment with azathioprine and anti-lymphocytic globulin].
Munch Med Wochenschr. 1971 Feb 12;113(7):221-31.
9
[Prospects of an immunologic therapy of multiple sclerosis].
Acta Neurol (Napoli). 1972 Jul-Aug;27(4):367-78.
10
[Treatment of multiple sclerosis (recent concepts)].
Rev Med Liege. 1972 Aug 15;27(16):543-6.
Zotero 插件